Brian Cheng
Stock Analyst at JP Morgan
(0)
# 4861
Out of 5,293 analysts
68
Total ratings
30.77%
Success rate
-28.88%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AAPG Ascentage Pharma Gro... | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Mar 27, 2025 | |
ITOS ITeos Therapeutics | Maintains: Overweight | 22 15 | 5.63 | 166.43% | 3 | Mar 6, 2025 | |
PTGX Protagonist Therapeu... | Maintains: Overweight | 53 57 | 46.87 | 21.61% | 5 | Mar 4, 2025 | |
NTLA Intellia Therapeutic... | Downgrades: Neutral | 45 13 | 6.64 | 95.78% | 4 | Feb 28, 2025 | |
BPMC Blueprint Medicines | Maintains: Overweight | 126 129 | 86 | 50% | 2 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 18 | 11.6 | 55.17% | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 27 28 | 9.69 | 188.96% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 51 46 | 15.18 | 203.03% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 39 33 | 1.98 | 1566.67% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 6 | 1.31 | 358.02% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 24 | 6.26 | 283.39% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 | 0.33 | 1415.15% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 8 | 1.36 | 488.24% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 16 15 | 9.85 | 52.28% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 17 14 | 0.35 | 3900% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | n/a | n/a | n/a | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 6 | 0.74 | 710.81% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 24 | n/a | n/a | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 33 39 | n/a | n/a | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 1.74 | 1049.43% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 71 85 | 9.43 | 801.38% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 21 | 7.25 | 189.66% | 1 | Aug 3, 2021 |